Evidence map›Paper›PMID 35304630›Full record

ArticleJournal of cancer research and clinical oncology2023

Optimizing the tumor shrinkage threshold for evaluating immunotherapy efficacy for advanced non-small-cell lung cancer.

Wei Du, Chen Chen, Lin-Feng Luo, Li-Na He, Yixing Wang, Xuanye Zhang, Yixin Zhou, Zuan Lin, Shaodong Hong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wei Du *State Key Laboratory of Oncology in South China, Guangzhou, China.
Chen Chen *State Key Laboratory of Oncology in South China, Guangzhou, China.
Lin-Feng LuoState Key Laboratory of Oncology in South China, Guangzhou, China.
Li-Na HeState Key Laboratory of Oncology in South China, Guangzhou, China.
Yixing WangState Key Laboratory of Oncology in South China, Guangzhou, China.
Xuanye ZhangState Key Laboratory of Oncology in South China, Guangzhou, China.
Yixin ZhouState Key Laboratory of Oncology in South China, Guangzhou, China.
Zuan LinState Key Laboratory of Oncology in South China, Guangzhou, China.
Shaodong HongState Key Laboratory of Oncology in South China, Guangzhou, China. hongshd@sysucc.org.cn.ORCID http://orcid.org/0000-0002-5632-6857

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe rise of immune checkpoint inhibitors (ICIs) in recent years has coincided with unusual clinical response patterns. Modification of the sum of longest diameters (SLD)-based threshold that reflecting dynamic change of the tumor burden and predicting response to ICIs, may markedly improve current treatment regimens.

methodsThe baseline and post-treatment SLD of target lesion was recorded and the maximum percent change of the SLD from baseline was designated as SLD-change score. The optimal cut-off value was obtained using the X-tile program. The relationship between SLD-change score and survival outcome (PFS, OS) was evaluated.

results10% cut-off value of SLD-change score was found to be most distinctive for PFS. Responders defined according to this cut-off value showed a significant improvement for PFS and OS. Bone metastasis and brain metastasis were also two independent prognostic factors of PFS and OS, respectively.

conclusions10% SLD change score could discriminate for ICIs treatment response, which holds great promise in promoting the development of precise immunotherapeutic strategy.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansImmunotherapyTreatment OutcomeCheck point inhibitorsImmunotherapyNon-small cell lung cancerRECISTSLD

Identifiers

PMID35304630
PMCPMC11797719

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.